Rare Disease Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
NORD makes the case that FDA should codify unconventional approaches by arguing that the agency already uses them for two-thirds of its orphan approvals.
You may also be interested in...
PDUFA VI: NORD Wants Reviewers To Be More Accessible
As rare disease experts become part of orphan drug reviews, stakeholder group says they also should be more accessible to the public.
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.
Regulatory Flexibility For Rare Diseases: How Do You Routinize Elasticity?
FDA tries to MaPP out how and when reviewers can be flexible, moving from 'one-off' to 'boutique' evaluation.